HEERLEN, Netherlands, Aug. 2, 2022 /PRNewswire/ --
Highlights1,2,3
Continuing operations:
Total Group:
Key figures – continuing operations
in € million |
H1 2022 |
H1 2021 |
% Change |
Volume |
Price/mix |
FX |
Other |
Sales |
4,115 |
3,517 |
17 % |
2 % |
8 % |
5 % |
2 % |
HNB |
4,076 |
3,471 |
17 % |
2 % |
8 % |
5 % |
2 % |
ANH |
1,839 |
1,581 |
16 % |
-1 % |
11 % |
6 % |
|
HNC |
1,464 |
1,260 |
16 % |
5 % |
4 % |
7 % |
|
F&B |
753 |
609 |
24 % |
5 % |
5 % |
5 % |
9 % |
Adjusted EBITDA |
746 |
693 |
8 % |
||||
HNB |
794 |
741 |
|||||
Corporate |
-48 |
-48 |
|||||
Adjusted EBITDA margin |
18.1 % |
19.7 % |
|||||
HNB |
19.5 % |
21.3 % |
1 |
Following the reclassification of DSM's Materials businesses to Discontinued Operations, Continuing Operations now reflects the results of DSM's Health, Nutrition & Bioscience and Corporate Activities. Please refer to page 2 for more details. |
2 |
DSM's Health, Nutrition & Bioscience structure became effective as of 1 January 2022. Please refer to page 2 for more details. |
3 |
Adjusted EBITDA is an Alternative Performance Measure (APM) that reflects results from usual operations. Organic sales growth is the total impact of volume and price/mix. Adjusted Net Operating Free Cash Flow is the cash flow from operating activities, corrected for the cash flow of the APM adjustments, minus the cash flow of capital expenditures and drawing rights. |
Co-CEOs statement
Geraldine Matchett and Dimitri de Vreeze, Co-CEOs, commented: "Our Health, Nutrition & Bioscience businesses delivered a good half year performance, underpinned by resilient market demand and strong pricing. We are proud of our people who continue to deliver for our customers navigating difficult supply chain conditions. Whilst acknowledging the challenging global macroeconomic environment, we see continuing good market demand, positive pricing momentum and favorable foreign exchange effects supporting our full year outlook.
The first half marked a pivotal moment in our history as we reached the final phase of our exciting strategic transformation. We announced our intention to merge with Firmenich, the world's largest privately-owned fragrance and taste company, to create the leading creation and innovation partner in nutrition, beauty and well-being. We also reached agreement to sell our two remaining Materials businesses.
As a purpose-led company, we are also accelerating our route to net zero again by enhancing our renewable electricity and greenhouse gas emissions reduction targets, as we constantly seek to enhance our positive impact for all stakeholders."
Outlook 2022
Following the announcements in April and May 2022 of the intended sale of DSM's two remaining Materials businesses, these are now reported as assets held for sale and as Discontinued Operations. Going forward, DSM will only provide an outlook for its Continuing Operations (Health, Nutrition & Bioscience, and Corporate Activities). The outlook for these continuing activities is unchanged: DSM expects to deliver a high-single digit Adjusted EBITDA increase.
Strategy
DSM's purpose-led, performance-driven strategy has sustainability and innovation as key growth drivers of a long-term focused plan, underpinned by ambitious targets across People, Planet and Profit.
New Health, Nutrition & Bioscience organization reporting from 2022
In September 2021, DSM announced the acceleration of its strategic journey to become a fully-focused Health, Nutrition & Bioscience ('HNB') company, organized, as from 1 January 2022, in three market-focused business groups: Animal Nutrition & Health, Health, Nutrition & Care and Food & Beverage.
This structure enables DSM to leverage its strong combination of scientific competences and growing portfolio of nutrition and health solutions, as well as harness the latest advancements in digital technology and bioscience, to address the significant environmental and societal challenges associated with the global food systems.
Recent acquisitions and disposals
On April 20, 2022 DSM announced that it had reached an agreement to sell its Protective Materials business to Avient Corporation for an Enterprise Value of €1.44 billion. DSM expects to receive €1.33 billion net in cash following closing, after transaction costs and capital gains tax. Completion of the transaction, which is only subject to customary conditions and approvals, is expected in H2 2022.
On May 31, 2022 DSM announced that it had reached an agreement to sell its Engineering Materials business to Advent International and LANXESS for an Enterprise Value of €3.85 billion. DSM expects to receive about €3.5 billion net in cash following closing, after transaction costs and capital gains tax. Completion of the transaction, which is only subject to customary conditions and approvals, is expected in H1 2023.
DSM has reclassified these businesses as assets held for sale and presented them in the Discontinued Operations in the Income Statement. Continuing Operations now reflects the results of the three HNB business groups and Corporate Activities.
Following these changes, DSM has published prior year restated comparative figures.
Merger
On May 31, 2022 DSM and Firmenich announced that they have entered into a business combination agreement to establish the leading creation and innovation partner in nutrition, beauty and well-being. DSM and Firmenich anticipate that the proposed combination will close in H1 2023. All related information can be found at www.creator-innovator.com.
Sustainability
DSM aims to create value for all stakeholders through the focused development of scientific innovation and the application of a growing portfolio of solutions that positively impact people and the planet, in line with its long-term purpose-led, performance-driven strategy. This approach is reinforced by improvements in the sustainability of DSM's own operations, continually raising safety and quality standards, and promoting health and well-being throughout its workforce.
Planet targets progress
During the first half of 2022 DSM made further progress on its path to reaching net-zero greenhouse gas emissions across its value chain by 2050. Initiatives include installing state-of-the art cooling machines in multiple sites in China and working with major suppliers to introduce greenhouse gas emissions reduction assets.
Building on its rapid actions over recent years, DSM has now announced an acceleration of its plan to purchase electricity from renewable sources, targeting 100% purchased renewable electricity worldwide by 2030, up from 75%. Within this context, DSM has also submitted revised scope 1 and 2 emissions reduction targets to the Science Based Targets initiative (SBTi) for independent assessment. The outcome is expected later this year. DSM will also move from a relative intensity target for the reduction of indirect value chain GHG emissions (scope 3), to an absolute reduction target. The exact target is being finalized and will be proposed for validation with the SBTi next year.
To better support DSM's customers to also deliver sustainable and healthy solutions, DSM has developed a new methodology for product portfolio steering which will allow for greater comparability, support reporting against new and future requirements of regulating authorities, plus create transparency on our contribution towards achieving the UN Sustainability Development Goals. Details of this methodology are available here.
DSM remains committed to obtaining reasonable assurance on its impact reporting. This includes quantifiable progress against the commitments announced in September 2021 aimed at addressing urgent societal and environmental challenges linked to how the world produces and consumes food.
People targets progress
DSM's long-standing priority remains the safety, health and well-being of people. The company continued to take proactive measures to support employees and their families during the first half of 2022, expanding local health initiatives and facilitating hybrid working where feasible. DSM has also continued to make progress on its broad inclusion and diversity efforts, endorsing highly motivated employee resource groups and accelerating female representation at the executive level. DSM's improvement in recordable safety incidents reversed after reaching all-time lows in January. With the company striving to be incident and injury free, DSM has increased face-to-face trainings with site visits now feasible again following COVID-19 limitations.
Q2 Highlights
Continuing Operations results:
Key figures – continuing operations
in € million |
Q2 2022 |
Q2 2021 |
% Change |
Volume |
Price/mix |
FX |
Other |
Sales |
2,107 |
1,790 |
18 % |
1 % |
8 % |
7 % |
2 % |
HNB |
2,089 |
1,760 |
19 % |
2 % |
8 % |
7 % |
2 % |
ANH |
958 |
803 |
19 % |
0 % |
11 % |
8 % |
|
HNC |
738 |
635 |
16 % |
2 % |
5 % |
9 % |
|
F&B |
391 |
313 |
25 % |
3 % |
7 % |
6 % |
9 % |
Adjusted EBITDA |
379 |
360 |
5 % |
||||
HNB |
403 |
382 |
|||||
Corporate |
-24 |
-22 |
|||||
Adjusted EBITDA margin |
18.0 % |
20.1 % |
|||||
HNB |
19.3 % |
21.7 % |
The second quarter saw resilient market demand, strong pricing, and more favorable foreign exchange effects.
Animal Nutrition & Health performed well, except in China where consumer demand suffered from COVID-19 lockdowns.
Both Health, Nutrition & Care, and Food & Beverage had a good quarter with sales supported by continued good market demand and successful pricing initiatives, partly offset by some product shortages resulting in order backlogs.
Overall, conditions improved during the quarter with a strong volume and price momentum in June and going into Q3.
Adjusted EBITDA was up 5% with 1% contribution from M&A and 6% from foreign exchange effects, with the COVID-19 lockdowns impact in China estimated to be about 3%. Higher prices largely offset the continuously rising energy, input and logistics costs, albeit with a time lag.
This resulted in an Adjusted EBITDA margin of 19.3% for HNB that reflects the dilutive mathematical effect of these price increases and foreign exchange effects of 160 bps. Without this effect, the margin would have been around 21%.
Note for editors: for the full text of the press release see accompanying pdf or click here.
Financial calendar
1 November 2022 Publication of the trading update first nine months of 2022
Additional information
Today DSM will hold a webcast for investors and analysts at 14:00 CEST. Details on how to access this call can be found on the DSM website, www.dsm.com.
Contact information
DSM Media Relations Gareth Mead tel. +31 (0) 45 5782420 email media.contacts@dsm.com |
DSM Investor Relations Dave Huizing tel. +31 (0) 45 5782864 |
DSM
Royal DSM is a global, purpose-led company in Health, Nutrition & Bioscience, applying science to improve the health of people, animals and the planet. DSM's purpose is to create brighter lives for all. DSM's products and solutions address some of the world's biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders – customers, employees, shareholders, and society at large. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at www.dsm.com.
Or find us on:
Facebook: http://www.facebook.com/DSMcompany
Twitter: http://www.twitter.com/DSM
LinkedIn: http://www.linkedin.com/company/3108
YouTube: http://www.youtube.com/user/dsmcompany
Forward Looking Statements
This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
Photo - https://mma.prnewswire.com/media/1870503/DSM_H1_2022_Sustainability_Results.jpg
Logo - https://mma.prnewswire.com/media/329419/dsm_logo.jpg
PDF - https://mma.prnewswire.com/media/1870504/DSM_presentation_to_investors_h1_2022.pdf
The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.
